PingAn Good Doctor Partners to Establish Lifestyle Medicine
China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor,...
Diabetes
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...
Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...
China Updates Hypertension Guidelines, Lowers Diagnostic Threshold
The National Center for Cardiovascular Diseases, the Chinese Medical Doctor Association (CMDA), and other organizations...
Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance
Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...
Eccogene Gains FDA Approval for Phase I Study of ECC5004
Shanghai-based Eccogene has announced receiving approval from the US FDA to initiate a Phase I...
Shanghai SMPA Suspends HEC’s Linagliptin Procurement Over Patent Infringement
The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has revealed that it has suspended the...
Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China
China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...
United Labs Gains NMPA Approval for Ozempic Biosimilar IND
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products...
YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval
China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...
Sciwind Biosciences Initiates US Phase I Study for GLP-1 Agonist XW014
China-based Sciwind Biosciences Co., Ltd has announced the initiation and first patient dosing of a...
Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes
China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been...
Tasly Pharmaceuticals Gains NMPA Approval for B1344 Diabetes Study
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...
CMS’s Rxilient Medical Licenses Insulin Products from Hefei Tianmai Biotech
China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd...
Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial
China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...
Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA)...
CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...
Gan & Lee Pharmaceuticals’ GZR4 Wins FDA Approval for Diabetes Treatment
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval...
Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME
China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...
Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...